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Abstract. Neuroblastoma is an aggressive pediatric tumor 
that accounts for 15% of cancer-related deaths in children. 
More than half of high-risk neuroblastoma patients develop 
tumor relapse that is lethal in most cases. A small popula-
tion of tumor-initiating cells (TICs), recently identified from 
high-risk neuroblastoma patients as spheres, is believed to be 
responsible for tumor relapse. Rab family small G proteins are 
essential in controlling membrane traffic and their misregula-
tion results in several cancers. Rab15 was originally isolated as 
a brain-specific Rab protein regulating the endocytic recycling 
pathway and was recently identified as a downstream target of 
the neural transcription factor Atoh1. Previously, we identified 
two alternatively spliced Rab15 isoforms in neuroblastoma 
cells and showed a significant correlation between Rab15 
expression and neuronal differentiation. As aberrant alternative 
splicing is intimately associated with an increasing number of 
cancers, its use as a new diagnostic and/or prognostic biomarker 
has attracted considerable attention. In the present study, 
we explored cancer-associated changes of Rab15 alternative 
splicing in neuroblastoma TICs. We found that Rab15 alternative 
splicing generated two novel isoforms designated as Rab15AN2 
and Rab15AN3 in addition to two known isoforms designated as 
Rab15CN and Rab15AN1. Although both Rab15AN2 and Rab15AN3 
contained premature termination codons, they were detected in 
not only neuroblastoma cells but also in normal human tissues. 
One isoform was predominantly expressed in the brain and testis, 
while the other isoform was more specifically expressed in the 
brain. In neuroblastoma, Rab15 isoform balance measured by 
the Rab15CN/Rab15AN1+AN2+AN3 ratio was significantly decreased 
in spheres compared to parental cells. These results suggest that 
Rab15 alternative splicing may serve as a biomarker to discrimi-
nate TICs from non-TICs in neuroblastoma.
Introduction
Neuroblastoma is the most commonly diagnosed cancer in the 
first year of life, and accounts for approximately 15% of all 
cancer-related deaths in the pediatric population. Although 
outcomes in neuroblastoma patients have improved steadily 
over the last 30 years, 50-60% of high-risk neuroblastoma 
patients are estimated to experience relapse. Consequently, 
their overall survival rates remain less than 40% despite 
more aggressive therapies (1-3). A growing body of evidence 
demonstrates that tumor-initiating cells (TICs) are present in 
most tumors and are responsible for sustaining tumor growth, 
progression, metastases and relapse (4-6). While many 
tumors regress after treatments that target proliferating tumor 
cells, inherent resistance of TICs leads to tumor relapse (7). 
Neuroblastoma TICs were recently identified as spheres grown 
in serum-free non-adherent culture used for neural crest stem 
cell growth and were shown to express stem cell markers, to 
have the ability to self-renew and differentiate into multiple 
cell types, and to form metastatic tumors in immunodeficient 
mice (8).
Rab family small G proteins that constitute more than 
60 members in humans play a key role in the spatiotemporal 
regulation of membrane traffic. Each Rab protein recognizes 
distinct subsets of intracellular membranes and controls the 
specific membrane transport pathways. Rab proteins function 
as a molecular switch cycling between ‘inactive’ GDP-bound 
and ‘active’ GTP-bound forms. The GTP-bound Rab protein 
interacts with their effector protein(s) that mediate the specific 
function of each Rab protein (9-11). It is becoming clear that 
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the functional alteration of Rab proteins can result in several 
types of cancer (12). In genomic amplicons of ovarian and 
breast cancers, Rab25 and its effector Rab-coupling protein 
(RCP), which regulate the endocytic recycling pathway, are 
identified as cancer driver genes (13,14). In melanoma, Rab27A 
that controls melanosome transport is implicated in cancer 
progression (15).
Rab15 was originally isolated as a brain-specific Rab 
protein regulating the endocytic recycling pathway and was 
recently identified as a downstream target of the neural basic 
helix-loop-helix (bHLH) transcription factor Atoh1 (16-18). 
We previously identified two alternatively spliced Rab15 
isoforms in neuroblastoma cells and showed the significant 
correlation between Rab15 expression and neuronal differen-
tiation (19). Alternative splicing produces multiple mRNAs 
from a single gene and represents the most prominent mecha-
nism generating mRNA diversity. More than 90% of human 
genes undergo alternative splicing in a highly development- 
and tissue-specific manner. Although the association between 
differential expressions of alternatively spliced isoforms and 
cancer progression are shown for only a handful of genes, the 
identification of an increasing number of cancer-associated 
alternative splicings has attracted considerable attention to use 
them as a new diagnostic and/or prognostic biomarker (20-22). 
In the present study, we identified and characterized two novel 
Rab15 isoforms in spheres of neuroblastoma cells.
Materials and methods
Neuroblastoma cells. Human neuroblastoma BE(2)-C cells 
were obtained from ATCC (Manassas, VA). NBTT2D cells 
were previously described (19). NBTT1 and NBTT3 cells were 
generated as previously described (19). Briefly, tumor samples 
were obtained from patients with high-risk neuroblastoma who 
were admitted to Hyogo Children's Hospital and gave written 
informed consent approved by the Hyogo Children's Hospital 
Ethics Board. The samples were handled in accordance with 
the Guidelines for Clinical Research of Kobe University 
Graduate School of Medicine. Tumor tissue samples were 
collected, cut into 2-3 mm3 pieces, enzymatically dissociated 
with Liberase DH (Roche, Mannheim, Germany) in PBS for 
15-45 min at 37˚C followed by the addition of 10% FBS to 
inhibit enzyme activity, and filtered through a 100-µm cell 
strainer (BD Biosciences, Bedford, MA). The resulting tumor 
tissue cells were washed with PBS, cultured at 37˚C (5% CO2 
and 95% air) in complete medium consisting of Dulbecco's 
modified Eagle's medium (DMEM)/Ham's F12 (Wako Pure 
Chemical; Osaka, Japan) and 10% fetal bovine serum (FBS; 
Invitrogen, Carlsbad, CA).
Cell culture. Neuroblastoma cells were cultured at 37˚C (5% 
CO2 and 95% air) in complete medium consisting of DMEM/
Ham's F12 (Wako Pure Chemical) and 10% FBS (Invitrogen) 
and subcultured by 0.25% trypsin-EDTA (Invitrogen). 
Phase-contrast images of parental cells were acquired using a 
BZ-9000E fluorescence microscope (Keyence, Osaka, Japan).
Sphere culture. Neuroblastoma spheres were cultured as 
previously described (23). Briefly, neuroblastoma cells were 
cultured at 37˚C (5% CO2 and 95% air) in sphere medium 
consisting of DMEM/Ham's F12 (3:1, Invitrogen), 100 units/ml 
penicillin/streptomycin (PC/SM; Invitrogen), 2% B27 supple-
ment (Invitrogen), 40 ng/ml basic fibroblast growth factor 
(bFGF; R&D Systems, Minneapolis, MN), and 20 ng/ml 
epidermal growth factor (EGF; R&D Systems), subcultured 
by non-enzymatic cell dissociation solution (Sigma, St. Louis, 
MO), and maintained for >4 weeks in Ultra-low attachment 
culture dishes (CORNING, Corning, NY). Phase-contrast 
images of spheres were acquired using a BZ-9000E fluores-
cence microscope (Keyence).
cDNA cloning of novel alternatively spliced Rab15 isoforms. 
Total RNA from spheres of BE(2)-C cells was isolated with 
the RNeasy Mini kit (Qiagen, Valencia, CA) and reverse 
transcribed using the PrimeScript II first strand cDNA 
Synthesis kit (Takara, Otsu, Japan). The full-length Rab15CN 
cDNA was amplified by PCR using PrimeStar GXL DNA 
Polymerase (Takara) and cloned into pCMV6-AN-GFP 
(OriGene, Rockville, MD). The resulting plasmid DNAs from 
nine independent clones was sequenced using an ABI Prism 
3100 Genetic Analyzer (Applied Biosystems, Foster City, CA). 
The cDNA sequences of Rab15 isoforms were submitted to 
the DDBJ/EMBL/GenBank nucleotide sequence databases 
under accession numbers AB678453 for Rab15CN, AB678452 
for Rab15AN1, AB672631 for Rab15AN2, and AB672632 for 
Rab15AN3.
Quantitative real-time RT-PCR. Human tissue total RNA was 
purchased from Clontech (Palo Alto, CA). Total RNA from 
neuroblastoma cells was isolated with the RNeasy Mini kit 
(Qiagen) and reverse transcribed using the QuantiTect Reverse 
Transcription kit (Qiagen). Real-time PCR analysis was 
performed with an ABI 7500 Fast Real-time PCR System 
(Applied Biosystems) using FastStart Universal SYBR-Green 
Master (Roche) according to the manufacturer's instructions. 
Each sample was analyzed in triplicate. Relative mRNA 
expression of Rab15CN, Rab15AN1, Rab15AN2, and Rab15AN3 to 
PGK1 and Rab15 isoform balance were calculated by the 
comparative CT method. Primers for Rab15CN (AB678453) 
were 5'-AGAGATACCAGACCATCACA-3' (sense) and 
5'-TTCTGGTGCGTACTCATCCACGTC-3' (antisense), 
Rab15AN1 (AB678452) were 5'-TACAGATCTGGGACAC 
TGCA-3' (sense) and 5'-CCGGCAGTGAGGTGGCATCT-3' 
(antisense), Rab15AN2 (AB672631) were 5'-AGAGATACCAG 
ACCATCACA-3' (sense) and 5'-CCGTGGAGGCCTCATC 
CACGT-3' (antisense), Rab15AN3 (AB672632) were 5'-AGAG 
ATACCAGACCATCACA-3' (sense) and 5'-GGTATCAGA 
GCTCATCCACGT-3' (antisense), and phosphoglycerate 
kinase 1 (PGK1, NM_000291) were 5'-GGAGAACCTCCG 
CTTTCAT-3' (sense) and 5'-GCTGGCTCGGCTTTAACC-3' 
(antisense).
Results
Identification of novel alternatively spliced Rab15 isoforms. 
We previously identified two alternatively spliced Rab15 
isoforms designated as Rab15CN and Rab15AN and showed that 
Rab15 isoform balance measured by the Rab15CN/Rab15AN ratio 
was significantly increased during neuronal differentiation of 
neuroblastoma cells (19). As aberrant alternative splicing is 
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intimately associated with an increasing number of cancers, 
its use as a new diagnostic and/or prognostic biomarker has 
attracted considerable attention. Therefore, we examined 
cancer-associated changes of Rab15 alternative splicing in 
spheres of neuroblastoma cells, in which TICs were highly 
enriched (8). When BE(2)-C cells were cultured in a serum-
free non-adherent condition, they efficiently formed spheres as 
previously described (23) (Fig. 1A). To detect cancer-associated 
changes of Rab15 alternative splicing, we first cloned the full-
length Rab15CN (AB678453) cDNA from spheres of BE(2)-C 
cells by RT-PCR. DNA sequencing of nine independent 
clones revealed the presence of three clones of novel Rab15 
isoforms in addition to four clones of Rab15CN and two clones 
of Rab15AN. One clone contained an 85-bp insertion (exon 4c) 
between exon 4 and exon 5 with a 360 bp open reading frame 
(ORF), whereas two clones had the identical 86-bp insertion 
(exon 4d) between exon 4 and exon 5 with a 330 bp ORF. 
Here, we designated exon 4c- and exon 4d-inserted clones as 
Rab15AN2 (AB672631) and Rab15AN3 (AB672632), respectively. 
Accordingly, we re-designated Rab15AN with a 627 bp ORF as 
Rab15AN1 (AB678452) (Fig. 1B).
Tissue distribution of Rab15AN2 and Rab15AN3. As Rab15AN2 
and Rab15AN3 contained premature termination codons that 
would cause the resulting mRNAs to be degraded by non-
sense-mediated mRNA decay (NMD) (24,25), we examined 
whether they were also expressed in normal human tissues 
by a quantitative real-time RT-PCR using the Rab15 isoform-
specific primers (Fig. 1B). Rab15AN2 and Rab15AN3 were 
detected in normal human tissues and showed a distinct tissue 
distribution pattern (Fig. 2). Rab15AN2 was predominantly 
expressed in the brain and testis, while Rab15AN3 was more 
specifically detected in the brain (Fig. 2). Together with the 
brain-specific Rab15CN and testis-specific Rab15AN1 expression 
(19), these results suggested that there were at least four alter-
natively spliced Rab15 isoforms, Rab15CN, Rab15AN1, Rab15AN2, 
and Rab15AN3, with distinct tissue distribution in humans.
Rab15 alternative splicing in parental cells and spheres 
of BE(2)-C cells. To analyze Rab15 alternative splicing in 
parental cells and spheres of BE(2)-C cells, we examined the 
expression of all Rab15 isoforms. In parental cells, Rab15CN 
was the most prevalent isoform and was expressed 13.2-fold 
more highly than the second most prevalent isoform, Rab15AN1 
(Fig. 3A). In spheres, Rab15CN was also the most prevalent 
isoform but was only expressed 6.1-fold more than the second 
prevalent isoform Rab15AN3 (Fig. 3B), suggesting that Rab15 
alternative splicing was considerably altered in spheres of 
BE(2)-C cells.
Rab15 isoform balance in normal human tissues. To evaluate 
Rab15 alternative splicing further, we examined Rab15 
isoform balance measured by the Rab15CN/Rab15AN1+AN2+AN3 
ratio in various human tissues. Consistent with our previous 
Figure 1. Identification of novel alternatively spliced Rab15 isoforms. (A) 
BE(2)-C cells were cultured either in a 10% serum adherent condition for 3 
days (parental cells) or in a serum-free non-adherent condition over 4 weeks 
(spheres) and examined by phase-contrast microscopy. The images shown 
are representative of three independent experiments. Scale bar, 100 µm. (B) 
The structure of the Rab15 gene, Rab15CN, Rab15AN1, Rab15AN2, and Rab15AN3. 
Arrows indicate the primers used for a real-time RT-PCR. The sequences of 
the primers are provided in the Materials and methods.
Figure 2. Tissue distribution of Rab15AN2 and Rab15AN3. The relative mRNA 
expression of Rab15AN2 to PGK1 (A) and Rab15AN3 to PGK1 (B) in various 
human tissues was analyzed by quantitative real-time RT-PCR. The mean 
expression in skeletal muscle was set to 1. The data shown are means ± SD of 
three independent experiments.
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observation (19), it was considerably varied, ranging from 0.6 in 
the testis to 4.3 in the heart (Fig. 4), suggesting that Rab15 alter-
native splicing was subjected to the tissue-specific regulation.
Altered Rab15 isoform balance in spheres of neuroblastoma 
cells. As Rab15 isoform balance measured by the Rab15CN/
Rab15AN1 ratio was significantly increased during neuronal 
differentiation of neuroblastoma cells (19), we here exam-
ined the Rab15 isoform balance measured by the Rab15CN/
Rab15AN1+AN2+AN3 ratio in parental cells and spheres of neuro-
blastoma cells. Because neuroblastoma cells displayed a 
considerable heterogeneity, we used three additional neuroblas-
toma cell lines designated as NBTT1, NBTT2D, and NBTT3 
from high-risk patients in addition to BE(2)-C cells (Table I). 
Compared to parental cells, Rab15 isoform balance was signifi-
cantly decreased in spheres of all BE(2)-C, NBTT1, NBTT2D, 
and NBTT3 cells (Fig. 5), suggesting that Rab15 alternative 
splicing was altered in spheres of neuroblastoma cells.
Discussion
In the present study, we found that Rab15 alternative splicing 
generated at least two novel isoforms in addition to two known 
isoforms and was altered in spheres of neuroblastoma cells. 
Neuroblastoma is believed to originate from neural crest cells 
that normally undergo sympathoadrenal differentiation (1-3). 
Although it is currently unclear whether neuroblastoma TICs 
arise directly from the normal neural crest cells or are derived 
from the de-differentiation of already transformed cells, 
TICs can be isolated as spheres (8). As spheres and parental 
cells were enriched in TICs and non-TICs, Rab15 alternative 
splicing was likely altered during the differentiation of neuro-
blastoma TICs into non-TICs.
Transcriptional profiling of normal and cancer cells leads to 
the identification of an increasing number of cancer-associated 
alternative splicing in a variety of cancers. Although these 
alternative splicings may not play any significant role in cancer 
progression, the association between differential expression 
of alternatively spliced isoforms and cancer progression has 
been validated for several genes (20-22). Aberrant expression 
of mouse double minute 2 (MDM2) isoforms is correlated 
with a poor prognosis in breast cancer (26). Isoform balance 
Figure 3. Rab15 alternative splicing in parental cells and spheres of BE(2)-C 
cells. The relative mRNA expression of Rab15CN, Rab15AN1, Rab15AN2, and 
Rab15AN3 to PGK1 was analyzed by quantitative real-time RT-PCR. The mean 
expression of Rab15AN2 was set to 1. The data shown are the means ± SD of 
three independent experiments.
Figure 4. Rab15 isoform balance in normal human tissues. Rab15 isoform 
balance measured by the Rab15CN/Rab15AN1+AN2+AN3 ratio was analyzed by 
quantitative real-time RT-PCR in various human tissues. The data shown are 
the means ± SD of three independent experiments.
Figure 5. Altered Rab15 isoform balance in spheres of neuroblastoma cells. 
Rab15 isoform balance measured by the Rab15CN/Rab15AN1+AN2+AN3 ratio was 
analyzed by quantitative real-time RT-PCR. The data shown are means ± SD 
of three independent experiments. *P<0.05, by the Student's t test.
Table I. Summary of cells isolated from clinical samples.
 Age  Tumor risk Specimen
Cells (years) Gender group type
 
NBTT1 6 Male High-risk Adrenal gland
NBTT3 2 Female High-risk Adrenal gland
The tumor risk group was based on the Children's Oncology Group 
Neuroblastoma Risk Stratification System (33). NBTT1 cells were 
derived from the same patient as the NBBM2 bone marrow cells 
described in our previous report (19).
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of hyaluronan synthase 1 (HAS1) and receptor for hyaluronan-
mediated motility (RHAMM) is shown to be a prognostic 
marker for multiple myeloma (27,28). In neuroblastoma, 
the expression of an alternatively spliced isoform of tumor 
suppressor p73, ∆Np73, is associated with reduced survival 
(29). Furthermore, cyclooxygenase inhibitors were shown to 
downregulate ∆Np73 expression and induce the other p73 
isoform, TAp73, providing a possible therapeutic way to 
modulate and/or correct cancer-associated alternative splicing 
(30). In the case of Rab15, whether alternatively spliced 
isoforms Rab15AN1, Rab15AN2, and Rab15AN3 have actual roles 
in neuroblastoma progression or are merely consequences of 
transformation is an open question for future study.
While we previously showed that Rab15CN expression was 
correlated with neuronal differentiation of neuroblastoma cells 
(19), Rab15 was recently identified as a downstream target of 
neural bHLH transcription factor Atoh1 that specified distinct 
neuronal subtypes of the proprioceptive pathway (18). Atoh1 
expression is known to control the normal development of 
the cerebellum and prevent medulloblastoma progression 
(31). In neuroblastoma cells, Atoh1 expression is regulated by 
β-catenin expression (32). It is tempting to speculate that the 
β-catenin-Atoh1-Rab15 system participates in some aspects 
of neuroblastoma progression. Together with our previous 
findings, the present study revealed that Rab15 isoform 
balance measured by the Rab15CN/Rab15AN1+AN2+AN3 ratio was 
significantly increased during differentiation of neuroblas-
toma cells, the differentiation of TICs into non-TICs as well 
as the neuronal differentiation (19). Because prognosis of 
neuroblastoma correlates with the degree of differentiation, 
Rab15 isoform balance may deserve further evaluation as a 
new prognostic biomarker.
In summary, we identified four Rab15 isoforms, Rab15CN, 
Rab15AN1, Rab15AN2, and Rab15AN3, in neuroblastoma cells, and 
demonstrated that Rab15 isoform balance measured by the 
Rab15CN/Rab15AN1+AN2+AN3 ratio was significantly decreased 
in spheres of neuroblastoma cells. The present study suggests 
that Rab15 alternative splicing may serve as a biomarker to 
discriminate TICs from non-TICs in neuroblastoma.
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